Etoricoxib

Critical Warnings & Restrictions — Patient Safety First

Basic Etoricoxib Information

• INN (International Nonproprietary Name): Etoricoxib
• Brand Names Available In United Kingdom: Arcoxia, Etoricoxib Accord
• ATC Code: M01AH05
• Forms & Dosages: Oral film-coated tablets 30 mg (rare), 60 mg, 90 mg, 120 mg
• Manufacturers In United Kingdom: MSD, Accord, Milpharm
• Registration Status In United Kingdom: MHRA-approved, Prescription Only Medicine (POM)
• OTC / Rx Classification: Prescription Only Medicine (POM)

High‑Risk Groups (Elderly, Pregnancy, Chronic Illness)

Etoricoxib is a Prescription Only Medicine (POM) in the United Kingdom and is MHRA approved for specific inflammatory pain conditions.

Screening must identify absolute contraindications before prescribing or dispensing, including hypersensitivity to etoricoxib or other coxibs, active peptic ulcer or gastrointestinal bleeding, and severe hepatic or renal impairment.

Established heart failure, uncontrolled hypertension, ischaemic heart disease, peripheral arterial disease or cerebrovascular disease are absolute contraindications to etoricoxib use.

Use extreme caution with elderly patients and those who have cardiovascular disease, renal impairment, hepatic disease or diabetes, and arrange regular monitoring of blood pressure, renal function and liver enzymes.

Pregnancy and breastfeeding: avoid etoricoxib as safety has not been established and obstetric guidance should be followed.

• Pre‑prescription Screening Checklist
• Ask about allergies and prior reactions to NSAIDs or coxibs.
• Confirm any current cardiovascular disease or risk factors.
• Check history of peptic ulcer disease or GI bleeding.
• Assess pregnancy, breastfeeding and contraception status if relevant.
• Review baseline renal and liver function tests and current blood pressure.

• Absolute Contraindications
• Hypersensitivity to etoricoxib or other coxibs.
• Active peptic ulcer or gastrointestinal bleeding.
• Severe hepatic impairment.
• Severe renal impairment (eGFR <30 mL/min).
• Heart failure, uncontrolled hypertension, established ischaemic heart disease, peripheral arterial disease, cerebrovascular disease.

• Relative Contraindications / Monitor Closely
• Elderly patients.
• Patients with diabetes, mild-to-moderate hepatic or renal impairment.
• Those with cardiovascular risk factors or taking multiple interacting medicines.

Document informed consent where risks are significant and provide the patient information leaflet at dispensing.

Advise patients to report suspected adverse reactions via the MHRA Yellow Card scheme.

Interaction With Activities (Driving, Workplace Safety)

Q&A — “Can I Drive After Taking It In The UK?”

Q: Can I drive after taking etoricoxib?

A: Etoricoxib can cause dizziness or drowsiness in some patients.

If a patient feels dizzy, drowsy or less alert after taking etoricoxib they should not drive or operate machinery.

For chronic users whose alertness may be affected, follow DVLA guidance and discuss with the GP or occupational health as needed.

Usage Basics — Names, Forms And Legal Status

INN, Common Brand Names And UK Formulations

Etoricoxib (INN; Latin: Etoricoxibum) is a highly selective COX‑2 inhibitor used for inflammatory pain and inflammation in conditions such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, chronic low back pain, acute gout and acute dental pain.

In the United Kingdom etoricoxib is marketed commonly as Arcoxia and as Etoricoxib Accord in generic form.

Available oral film-coated tablets are 30 mg (rare), 60 mg, 90 mg and 120 mg strengths with blisters commonly supplied in packs of 28 in the UK market.

No injectable or topical formulations are registered in the available product data.

Legal Classification (POM, P, GSL) And Prescribing Implications

POM

Prescription Only Medicine — requires a valid prescription for supply in the UK and is the classification for etoricoxib.

P

Pharmacy medicine — available from a pharmacist without a prescription; not applicable to etoricoxib.

GSL

General Sales List — medicines available without a pharmacist; not applicable to etoricoxib.

Pharmacists must check the indication, intended duration, allergy status and monitoring arrangements before supply and counsel patients on risks and follow‑up.

Patients should keep packaging and the leaflet for storage and transport guidance.

Dosing Guide — Standard Regimens And Adjustment

Standard NHS Regimens And Indication‑Based Doses

Typical adult dosing aligns with the Summary of Product Characteristics and NHS practice.

For osteoarthritis a usual dose is 30–60 mg once daily depending on response and tolerability.

For rheumatoid arthritis 60–90 mg once daily is typical, titrated to response where necessary.

Ankylosing spondylitis is commonly treated with 90 mg once daily.

Acute gout dosing is 120 mg once daily for up to eight days only.

Acute dental pain may be treated with 90 mg once daily for up to three days.

Etoricoxib is not indicated for children and paediatric safety has not been established.

Elderly patients do not require routine dose reduction unless renal or hepatic impairment is present, but monitoring is advised.

Adjustments For Comorbidities

Avoid etoricoxib in severe renal impairment with eGFR below 30 mL/min.

Use caution in mild to moderate renal dysfunction and monitor renal function regularly.

In hepatic impairment: for mild disease limit to a maximum of 60 mg per day.

For moderate hepatic impairment a suggested maximum is 60 mg every other day and etoricoxib is contraindicated in severe hepatic impairment.

In patients with raised cardiovascular risk consider alternatives rather than prescribing a COX‑2 selective agent.

Q&A — “What If I Miss A Dose?”

Q: What if I forget a dose?

A: Take the missed dose as soon as you remember unless the next scheduled dose is due soon.

Do not take a double dose to make up for a missed dose.

If there is uncertainty about timing or if multiple doses are missed, contact the GP or pharmacist for advice.

In the case of overdose seek emergency care; management is supportive as there is no specific antidote listed.

Interaction Chart — Drugs, Food And Monitoring

Food, Drink And Lifestyle Interactions

Alcohol can increase the risk of gastrointestinal bleeding and may exacerbate blood pressure effects while taking etoricoxib.

Advise patients to limit alcohol intake while on therapy.

No major specific food interactions are documented, but caffeine, dehydration and orthostatic factors may add to dizziness risk.

Encourage patients to maintain adequate fluid intake and avoid heavy alcohol consumption while taking etoricoxib.

Common Drug Interactions And MHRA Yellow Card Context

• Suggested monitoring plan: check blood pressure at baseline and periodically, monitor renal function (eGFR) and serum electrolytes, check liver enzymes at baseline and during treatment, and watch for signs of bleeding.
• Encourage reporting of suspected adverse drug reactions through the MHRA Yellow Card scheme.

User Reports & Trends — UK Patient Insight

Patients commonly ask whether etoricoxib will relieve persistent joint pain when ibuprofen or naproxen have not helped.

Collated feedback from NHS Choices, Patient.info and public forums shows common themes of effective pain relief for inflammatory joint pain using Arcoxia or etoricoxib 60–90 mg.

Frequent patient concerns include cardiovascular risk, peripheral oedema, new or raised blood pressure and how long a prescription can safely continue.

Many patients value pharmacist counselling at community chains such as Boots and LloydsPharmacy for side‑effect checks and monitoring advice.

• Patient‑Reported Benefits: rapid symptom relief for inflammatory pain and improved mobility for some patients.
• Patient‑Reported Harms: peripheral oedema, dizziness, increased blood pressure and transient digestive symptoms.
• Common Questions: duration of use, switching from other NSAIDs, monitoring frequency and prescription renewals.

Two anonymised patient quotes help balance the view: “It eased my shoulder pain within 48 hours but I had to stop when my ankles swelled.”

“My GP switched me from ibuprofen to etoricoxib and arranged a blood pressure check within two weeks.”

Clinician commentary: use etoricoxib when alternatives are unsuitable and ensure appropriate cardiovascular and renal review.

Forum Terms

“SPC” — Summary of Product Characteristics; “BP” — blood pressure; “OA” — osteoarthritis.

Access & Purchase Options In The United Kingdom

High‑Street Pharmacies And Chains

Etoricoxib is available only on prescription through high‑street pharmacies and NHS clinics in the UK, with common suppliers including Boots, LloydsPharmacy and Superdrug dispensing either Arcoxia or generic etoricoxib supplied by Accord or Milpharm.

NHS prescriptions are issued by GPs, urgent care centres or hospital outpatient clinics and may be dispensed at community pharmacies.

Online Pharmacies And E‑Prescriptions

NHS e‑prescription and accredited online pharmacies are increasingly used for convenient supply in the UK.

Always verify the pharmacy is registered with the General Pharmaceutical Council (GPhC) and require a valid prescription for etoricoxib supply.

Warning: illegitimate online sellers may offer prescription medicines without a prescription; check the MHRA and GPhC registers before ordering.

• Checklist For Safe Online Purchase: valid prescription, visible GPhC registration, contactable pharmacist, pharmacist counselling offered before supply.

In our online pharmacy, etoricoxib is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Mechanism & Pharmacology — How Etoricoxib Works

Simplified Explanation For Patients

Etoricoxib is a highly selective COX‑2 inhibitor that reduces production of prostaglandins involved in pain and inflammation.

By sparing COX‑1 to some extent, etoricoxib was developed to lower the risk of gastrointestinal adverse events compared with non‑selective NSAIDs, although cardiovascular risk remains a concern for susceptible patients.

Clinical Pharmacology Terms For Clinicians

ATC classification is M01AH05 for selective COX‑2 inhibitors.

Oral bioavailability and a relatively long half‑life support once‑daily dosing for most indications.

High protein binding contributes to distribution characteristics and interactions with other highly protein‑bound drugs should be considered.

COX‑1

Constitutive enzyme involved in gastric protection and platelet function.

COX‑2

Inducible enzyme largely responsible for inflammation and pain signalling.

Indications & Off‑Label Uses

MHRA‑Approved Indications

Approved indications include osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, chronic low back pain, acute gout and acute dental pain.

Recommended SPC dosing aligns with usual practice: osteoarthritis 30–60 mg, rheumatoid arthritis 60–90 mg, ankylosing spondylitis 90 mg, gout 120 mg for no more than eight days and dental pain 90 mg for up to three days.

Off‑Label Practice In NHS And Private Care

Etoricoxib may occasionally be used off‑label for other inflammatory pain conditions when alternatives are unsuitable and after careful risk assessment.

• Clinical Scenarios For Consideration: patients intolerant of non‑selective NSAIDs with significant GI history where COX‑2 selectivity may be beneficial.
• Clinical Scenarios For Consideration: complex musculoskeletal pain where short‑term high dose is required and benefits outweigh risks.
• Clinical Scenarios For Consideration: specialist‑led cases with documented rationale and safety monitoring.

When prescribing off‑label, document rationale clearly, discuss risks with the patient, obtain informed consent and arrange monitoring for blood pressure, renal function and liver enzymes.

Key Clinical Findings

Recent UK and EU trials and systematic reviews indicate etoricoxib provides effective symptom relief and functional improvement in osteoarthritis and inflammatory arthropathies comparable to other NSAIDs.

Comparative data show relative gastrointestinal sparing versus non‑selective NSAIDs, but a consistent signal of increased cardiovascular risk in high‑risk cohorts exists.

Regulatory guidance and the SPC emphasise limiting high doses and careful patient selection with monitoring.

• Efficacy: effective for inflammatory joint pain at recommended doses.
• Cautions: increased cardiovascular risk in susceptible patients and potential renal effects.
• Monitoring: baseline and periodic BP, renal and liver checks advised.

Local NHS audit of prescribing may improve appropriateness and identify adverse outcomes for reporting via local governance and the Yellow Card system.

Alternatives Matrix — NHS Prescribing Choices

Comparison Table

Pros And Cons Checklist

• Assess analgesic needs and severity of pain.
• Review cardiovascular risk and GI history before choosing a COX‑2 inhibitor.
• Prefer topical NSAIDs or paracetamol for low‑risk mild osteoarthritis.
• Avoid COX‑2 inhibitors in high cardiovascular risk unless specialist advice obtained.

Common Questions — Patient FAQs Distilled

How Long Can I Stay On Etoricoxib?

Duration depends on indication and risk profile; chronic conditions require periodic review.

Short courses are recommended for acute gout (max eight days) and dental pain (up to three days).

Can I Switch From Another NSAID To Etoricoxib?

Switching is possible but should follow a clinical review of response and tolerability, and monitoring of blood pressure and renal function should be arranged.

Is Etoricoxib Safe In Pregnancy Or Breastfeeding?

Pregnancy and breastfeeding: avoid etoricoxib as safety is not established; seek obstetric or midwifery advice.

What Monitoring Do I Need?

Baseline blood pressure, renal function (eGFR) and liver enzymes are advised with periodic follow‑up during treatment.

• If experiencing worrying symptoms such as black stools, chest pain, sudden swelling, shortness of breath or jaundice contact NHS 111 or your GP urgently.
• For severe or life‑threatening symptoms call 999 or attend emergency care.
• Report side effects to the MHRA Yellow Card scheme.

NHS Cost & Access Comparison Table

• How To Check Entitlement: use the NHS website or contact the local GP practice or pharmacy to confirm prescription exemptions.
• Repeat Prescriptions: request via NHS e‑prescription service or GP surgery; pharmacies may accept electronic repeat requests with appropriate authorisation.

Registration & Regulation — MHRA & Prescribing Framework

MHRA Approval And SPC

Etoricoxib is MHRA‑approved in the United Kingdom and prescribers should consult the Summary of Product Characteristics (SPC) for up‑to‑date contraindications, dosing and monitoring requirements.

EMA approval is in place for the EU and etoricoxib is not approved by the FDA in the USA.

NHS Prescribing Governance

Prescribers must follow local formularies, document indication, dose and review date in the patient record and obtain informed consent where higher doses are considered, such as 120 mg for gout.

• Checklist For Regulatory Compliance: verify current SPC, document rationale for prescribing, arrange baseline tests, set review dates and inform the patient of reporting routes.
• Pharmacist Responsibilities: verify prescription authenticity, check interactions and contraindications, provide counselling, advise on monitoring and safe disposal.

Storage & Handling — Household And Transport Guidance

Home Storage Advice For UK Climate

Store etoricoxib below 30°C, away from moisture and direct light, and keep in its original packaging to help avoid degradation.

Do not refrigerate etoricoxib tablets.

Keep medicines out of reach of children and pets and store them in a secure place.

Travel, Transport And Disposal

When travelling within the UK or abroad, carry etoricoxib in its original packaging with a copy of the prescription to prevent supply or customs issues.

For electronic prescriptions retain the e‑prescription ID or printed copy during travel.

• Travel Checklist: carry medicine in original blister pack, protect from heat and humidity, avoid storing in bathrooms.
• Disposal: return unused tablets to any community pharmacy for safe disposal and never flush medicines down the toilet.
• Signs Of Storage Damage: discolouration, broken blisters or unusual smell — do not use and return to pharmacy.

Guidelines For Proper Use — Pharmacist Counselling And NHS Patient Safety

Pharmacist Counselling Style (UK)

A structured consultation should confirm the indication, review past medical history, check current medicines and allergies, and assess blood pressure and renal/liver risk where indicated.

Counselling should cover dose, duration, expected benefits, common side effects and when to seek help for worrying symptoms.

• Counselling Template To Provide At Supply: indication, dose, monitoring schedule, driving and workplace safety, key interactions and how to report side effects via Yellow Card.

NHS Patient Safety Advice And Follow‑Up

Advise baseline and periodic monitoring for blood pressure, renal function and liver enzymes and schedule reviews for oedema, weight gain or GI bleeding.

Document review dates in NHS records and ensure repeat prescriptions are only issued after appropriate review.

• Safety Action Plan For Patients: seek urgent help for chest pain, sudden swelling, breathlessness, black or bloody stools, or jaundice.
• Who To Contact: local GP for routine queries, NHS 111 for urgent non‑emergency advice, pharmacist for medicine queries and MHRA Yellow Card for side‑effect reporting.

Delivery Across United Kingdom